Alexandria Real Estate Equities Welcomes Dr. Claire Aldridge to Its Board

Alexandria Real Estate Equities Expands Board with New Appointment

On March 6, 2025, Alexandria Real Estate Equities, Inc. (NYSE: ARE), a leader in developing collaborative life science environments, announced the election of Dr. Claire Aldridge to its Board of Directors. This exciting development, effective from March 14, 2025, aims to bolster the board's expertise, particularly in the life sciences field. Dr. Aldridge will also serve on the Life Science Committee, ensuring a focus on innovative working methodologies and strategic development within the sector.

Dr. Aldridge is no stranger to the life sciences industry, bringing more than 25 years of rich experience that spans multiple disciplines including biotechnology, venture capital, and AI-driven therapeutic advancements. As noted by Joel S. Marcus, the executive chairman and founder of Alexandria Real Estate Equities, Dr. Aldridge’s profound understanding of the commercial aspects of life sciences will significantly enhance the board's collective knowledge and decision-making capabilities.

Having previously held the position of Chief Strategy Officer at Form Bio, she played a pivotal role in integrating cutting-edge artificial intelligence into genomic analysis and development programs. Her commendable efforts included the facilitation of gene therapy advancements and the exhaustion of proprietary datasets for training sophisticated AI models. Before her tenure at Form Bio, Dr. Aldridge excelled as a senior vice president at Taysha Gene Therapies. Her journey through the biotechnology sector has been driven by a commitment to develop therapies that strive for better patient outcomes.

In addition to her new responsibilities at Alexandria, Dr. Aldridge holds advisory positions in several influential biotech organizations. She is on the scientific advisory board for Colossal Biosciences and also serves on the board of directors for 4E Therapeutics. As a founding advisor for Nucleate Texas, she seeks to pave the way for future leaders in biotechnology, guiding them through the complexities of the industry.

Moreover, her appointment adds to the recognition she received in April 2023 when she was named by Forbes as one of the ten leading women in the synthetic biology sector. This not only marks a personal achievement for Dr. Aldridge but also positions Alexandria Real Estate Equities as a forward-thinking organization that prioritizes leadership diversity.

Dr. Aldridge earned her PhD in Immunology from Duke University and holds a Bachelor of Science in Biomedical Science from Texas A&M University. This strong educational foundation complements her extensive experience and signifies her alignment with Alexandria’s mission of enhancing life through innovative real estate solutions tailored for the life sciences sector.

With a mission-driven approach, Alexandria has set itself apart since its inception in 1994. The company specializes in creating life science ecosystems that foster innovation and collaboration. With a current market capitalization of $29 billion, Alexandria’s portfolio includes an impressive compilation of operating properties and ongoing constructions in major life science hubs across the United States.

In conclusion, Dr. Aldridge’s election is not just a strategic move for Alexandria, but also a promise of enhanced governance that will shape the company's directions in the life sciences domain. Through her leadership, the board is set to explore new horizons, guaranteeing that Alexandria Real Estate Equities remains a pillar in the transformative landscape of life sciences.